My Colorectal Cancer has recurred. How does this change my treatment choices, and are new targeted therapies using...

According to the NCCN Guidelines for Colorectal Cancer (2023):

1. Biomarker testing is ESSENTIAL for recurrent disease and should include:

• RAS mutations (KRAS and NRAS)
• BRAF V600E mutation
• MSI (Microsatellite Instability) status
• HER2 amplification (particularly for left-sided tumors)

Treatment options based on biomarkers:

For MSI-High tumors:

• The NCCN and ASCO Guidelines recommend immunotherapy as a preferred option
• FDA-approved options include pembrolizumab or nivolumab (with or without ipilimumab)

For RAS Wild-Type tumors:

• NCCN Guidelines recommend EGFR inhibitors (like cetuximab or panitumumab) in combination with chemotherapy
• Location of tumor (left vs right side) may influence effectiveness

For BRAF V600E Mutated tumors: According to ESMO Guidelines:

• Targeted therapy combinations including BRAF inhibitors (encorafenib) plus cetuximab
• This combination was FDA-approved based on improved survival rates

Additional Considerations: The American Cancer Society emphasizes that treatment for recurrent disease typically involves:

• Combination of different treatment approaches
• Regular monitoring of biomarkers as they may change
• Clinical trial opportunities when available

Important recommendations:

1. Get comprehensive biomarker testing if not already done
2. Discuss results with your oncology team to determine the best treatment sequence
3. Consider clinical trial participation if appropriate

Remember: Treatment choices should be individualized based on:

• Your specific biomarker profile
• Location and extent of recurrence
• Previous treatments received
• Overall health status
• Personal preferences

Always consult with your healthcare team to develop the most appropriate treatment plan for your specific situation.